ANGO - AngioDynamics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.25
-0.52 (-2.63%)
At close: 4:00PM EDT

19.25 0.00 (0.00%)
After hours: 4:39PM EDT

Stock chart is not supported by your current browser
Previous Close 19.77
Open 19.72
Bid 18.86 x 800
Ask 24.50 x 1100
Day's Range 19.22 - 19.75
52 Week Range 18.11 - 25.48
Volume 157,297
Avg. Volume 252,401
Market Cap 716.406M
Beta (3Y Monthly) 0.70
PE Ratio (TTM) 159.09
EPS (TTM) 0.12
Earnings Date Jul 10, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 24.00
Trade prices are not sourced from all markets
  • Is AngioDynamics, Inc. (ANGO) A Good Stock To Buy?
    Insider Monkey yesterday

    Is AngioDynamics, Inc. (ANGO) A Good Stock To Buy?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • Business Wire 7 days ago

    AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019

    AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2019 before the market open on Wednesday, July 10, 2019.

  • AngioDynamics moving 125 employees into downtown Glens Falls
    American City Business Journals 21 days ago

    AngioDynamics moving 125 employees into downtown Glens Falls

    AngioDynamics will lease the 9th floor of the 10-story Monument Square building in a plan that will bring 125 employees into downtown Glens Falls. The medical device maker is taking approximately 15,000 square feet of office space to accommodate personnel, most of whom previously worked at 10 Glens Falls Technical Park, the former Navilyst building that was sold to Medline Industries last week for $5.75 million. The move is part of AngioDynamics' strategy to improve communication, restructure its manufacturing operations and build a stronger corporate culture, said Dave Helsel, senior vice president of global operations, research and development.

  • AngioDynamics Divests NAMIC Portfolio to Medline Industries
    Zacks 22 days ago

    AngioDynamics Divests NAMIC Portfolio to Medline Industries

    The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

  • Business Wire 23 days ago

    AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference

    AngioDynamics, Inc.  , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference at 1:50 p.m.

  • Business Wire 24 days ago

    AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC® fluid management portfolio to Medline Industries, Inc. on May 31, 2019 for $167.5 million. AngioDynamics has used a portion of the approximately $160.0 million in net proceeds to pay down all of its outstanding debt. “We are very pleased to have completed the divestiture of the NAMIC fluid management business, which is a critical step in our ongoing portfolio optimization efforts,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics.

  • Business Wire last month

    AngioDynamics to Ring NASDAQ Closing Bell to Celebrate the 15th Anniversary of its Listing on the Exchange

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock Market closing bell on Tuesday, May 28, 2019 at 4:00 p.m. ET to commemorate the 15-year anniversary of the Company’s listing on the exchange. “NASDAQ has provided AngioDynamics with a robust platform to access the public equity markets and connect with potential shareholders and investors,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics.

  • AngioDynamics IDE Application for NanoKnife Gets FDA Nod
    Zacks last month

    AngioDynamics IDE Application for NanoKnife Gets FDA Nod

    AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.

  • Business Wire last month

    AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation pilot study for the ablation of prostate cancer tissue in low-risk patients. The prospective, non-randomized pilot study includes six subjects at up to three clinical sites.

  • Business Wire last month

    AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

    The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. The first patient enrollment closely follows the United States Food and Drug Administration’s (FDA) April 1, 2019 approval of AngioDynamics’ investigational device exemption (IDE) application.

  • Here’s What Hedge Funds Think About AngioDynamics, Inc. (ANGO)
    Insider Monkey 2 months ago

    Here’s What Hedge Funds Think About AngioDynamics, Inc. (ANGO)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?
    Zacks 2 months ago

    Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?

    AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Benzinga 2 months ago

    The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

    Here's a roundup of top developments in the biotech space over the last 24 hours: No biotech stocks hit 52-week highs on Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on April 17) ABIOMED, ...

  • AngioDynamics will sell Namic business for $167.5 million
    American City Business Journals 2 months ago

    AngioDynamics will sell Namic business for $167.5 million

    The sale is expected to close by the end of May. Once that occurs, 330 to 350 AngioDynamics employees are expected to join Medline Industries Inc., a privately-held company headquartered near Chicago.

  • Business Wire 2 months ago

    AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that it has entered into a definitive agreement to sell its NAMIC® fluid management portfolio to Medline Industries, Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction consists of AngioDynamics’ NAMIC brand and its extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories.

  • Why AngioDynamics, Inc.’s (NASDAQ:ANGO) Return On Capital Employed Might Be A Concern
    Simply Wall St. 2 months ago

    Why AngioDynamics, Inc.’s (NASDAQ:ANGO) Return On Capital Employed Might Be A Concern

    Today we'll evaluate AngioDynamics, Inc. (NASDAQ:ANGO) to determine whether it could have potential as an investment idea. Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how e...

  • Business Wire 2 months ago

    AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB) approval to conduct its NanoKnife® Irreversible Electroporation “Direct IRE Cancer Treatment” clinical study (DIRECT). The IRB approval closely follows the United States Food and Drug Administration’s (FDA) approval of AngioDynamics’ investigational device exemption (IDE) application announced on April 1.

  • Thomson Reuters StreetEvents 3 months ago

    Edited Transcript of ANGO earnings conference call or presentation 2-Apr-19 12:00pm GMT

    Q3 2019 AngioDynamics Inc Earnings Call

  • AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates
    Zacks 3 months ago

    AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates

    Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.

  • AngioDynamics (ANGO) Q3 2019 Earnings Conference Call Transcript
    Motley Fool 3 months ago

    AngioDynamics (ANGO) Q3 2019 Earnings Conference Call Transcript

    ANGO earnings call for the period ending February 28, 1019.

  • AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study
    Zacks 3 months ago

    AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study

    AngioDynamics' (ANGO) launches AngioDIRECT.com for enrolling participants as part of the DIRECT clinical study.

  • AngioDynamics (ANGO) Lags Q3 Earnings and Revenue Estimates
    Zacks 3 months ago

    AngioDynamics (ANGO) Lags Q3 Earnings and Revenue Estimates

    AngioDynamics (ANGO) delivered earnings and revenue surprises of -13.64% and -2.44%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press 3 months ago

    AngioDynamics: Fiscal 3Q Earnings Snapshot

    The Latham, New York-based company said it had profit of 2 cents per share. Earnings, adjusted for one-time gains and costs, were 19 cents per share. The medical device maker posted revenue of $86.3 million ...

  • Business Wire 3 months ago

    AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results

    Fiscal 2019 Third Quarter Highlights

  • ACCESSWIRE 3 months ago

    AngioDynamics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 2, 2019 / AngioDynamics, Inc. (NASDAQ: ANGO ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on April 2, 2019 at 8:00 AM Eastern ...